Valuation: Biostax Corp.

Market Cap 1.34M 1.21M 1.12M 1.01M 1.91M 125M 1.98M 13.52M 5.35M 67.46M 5.02M 4.91M 213M P/E 2022
-6x
P/E 2023 -3.65x
Enterprise Value 2.49M 2.26M 2.09M 1.89M 3.56M 233M 3.7M 25.18M 9.96M 126M 9.35M 9.15M 397M EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
42.24%
Yield 2022 *
-
Yield 2023 -
1 day-50.00%
1 week-50.00%
Current month-50.00%
1 month-50.00%
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 0.0001
0
1 year 0
Extreme 0.0001
0
3 years 0
Extreme 0.0001
0.15
5 years 0
Extreme 0.0001
5.35
10 years 0
Extreme 0.0001
92.7
Manager TitleAgeSince
Chief Executive Officer 73 01/03/2012
Chief Executive Officer 55 03/11/2022
President - 01/08/2025
Director TitleAgeSince
Director/Board Member 53 31/05/2022
Director/Board Member 64 24/10/2023
Director/Board Member 52 08/11/2023
Date Insider Type Main position Quantity % Market Cap. Importance
2/10/23 A Buy

Chief Financial Officer

409,000 0.4925%
7/25/22 A Other

Chief Operating Officer

19,307,145 -
5/28/21 A Other 24,570 5.0985%
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-50.00%-.--%-99.86% 21.65K
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.64%+0.07%+9.57%+89.87% 60.41B
-1.07%+0.55%+21.79%+87.66% 55.76B
+0.48%-2.53%+9.73%+121.14% 46.98B
-2.69%-6.38%+19.19%+25.79% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.50%-15.73%+135.31%+662.73% 36.09B
-0.77%-4.34%+79.27%+59.47% 32.9B
-0.83%+1.98%-38.27%+390.98% 26.96B
Average -5.95%-1.53%+30.44%+145.40% 40B
Weighted average by Cap. -0.98%-1.48%+33.54%+147.81%

Financials

2022 2023
Net sales - -
Net income -3.54M -3.21M -2.97M -2.68M -5.05M -330M -5.24M -35.73M -14.13M -178M -13.27M -12.99M -563M -1.65M -1.5M -1.38M -1.25M -2.36M -154M -2.45M -16.68M -6.6M -83.22M -6.19M -6.06M -263M
Net Debt 546K 496K 458K 413K 780K 51.01M 810K 5.52M 2.18M 27.53M 2.05M 2.01M 86.97M 1.15M 1.05M 968K 873K 1.65M 108M 1.71M 11.66M 4.61M 58.19M 4.33M 4.24M 184M
Projected Income Statement - Annual - Biostax Corp.
Logo Biostax Corp.
Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.
Employees
4
  1. Stock Market
  2. Stocks
  3. BTAX Stock